Marcia A. Ryder, PhD MS RN FNAP: BD: Consultant (Ongoing); Eloquest Healthcare: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker's Bureau (Ongoing); HAI: Consultant (Ongoing), Grant/Research Support (Ongoing); ICU Medical: Consultant (Ongoing), Grant/Research Support (Ongoing)
The CLABSI rate in the U.S. decreased by 15% from 2022 to 2023. The dramatic reduction of CVC utilization undoubtedly had a significant impact on this reduction since many hospitals mandated the use of peripheral vascular access devices (PVADs) as a CLABSI reduction strategy. What about reduction in PVAD related BSI? More likely than not, the rate of peripheral device infection will be found to be much higher when HOB measures are established. Can the use of dressing securement technology prevent HOB? In this session, the microbial life under dressings, advancements in dressing securement technology, and the use of a point prevalence assessment tool for surveillance of VAD dressing and skin integrity will be presented.
Learning Objectives:
1. Understand the microbiology of vascular access device insertion site and circumferential skin of intact and non-intact dressings.
2. Explain the correlation of loss of dressing integrity and CRBSI/HOB.
3. Examine the key strategies for the prevention of extraluminal source of CRBSI:
site selection, skin antisepsis, ANTT, and dressing integrity and securement
4. Consider the benefits of using a VAD Point Prevalence Assessment Tool for monitoring and surveillance of dressing and skin integrity.
